Inclusion Criteria:

* Diagnosis of overactive bladder (OAB) with or without urgency urinary incontinence
* Symptoms of OAB for at least 3 months prior to the Baseline Visit
* Willing and able to complete electronic patient-reported outcomes questionnaires monthly for a minimum of 1 year
* Previous exposure to anticholinergics or mirabegron monotherapy and/or mirabegron plus solifenacin combination therapy prior to initiation of vibegron

Exclusion Criteria:

* Any contraindication to the use of vibegron per the United States label
* History of OAB treatment with botulinum toxin A; sacral neuromodulation; percutaneous tibial nerve stimulation; external beam radiation therapy; urinary stents within the last 6 months; pelvic or lower urinary tract surgery within the last 6 months; and urethral catheterizations within the last 3 months prior to the Baseline Visit
* History of mixed incontinence where stress incontinence is the predominant form (as determined by the investigator)
* Participants at risk of urinary retention (as determined by the investigator)
* Neurologic conditions associated with OAB symptoms, e.g., multiple sclerosis
* Pregnant or breastfeeding or plans to do so during the study
* Use of vibegron prior to the Baseline Visit either prescribed or in a previous vibegron clinical trial where the participant was on vibegron
* Anyone who, at the discretion of the investigator, is not suitable for treatment with a beta 3 agonist for OAB for any reason